Drugs / LY4298445
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07276958 | Feb 2026 → Mar 2028 expected | rheumatoid arthritis, systemic lupus erythematosus | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY4298445 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07276958 ↗ |
| Route | Subcutaneous | “Administered SC” NCT07276958 ↗ |